Biostatistician Jeffrey Morris discusses his analysis of the vaccine monitoring system — and how it could be improved.

The New York Times once called John Lamattina, then Pfizer head of R&D, “Dr. Optimistic.” He’s not so optimistic now.

The following is the transcript of the interview with former FDA commissioner Scott Gottlieb, who now serves on the boards of Pfizer and United Healthcare, that aired on "Face the Nation with Margaret ...

Pfizer’s stock rebounded from April lows yet still trades as if COVID and patent cliffs equal business ruin, despite resilient non‑COVID franchises and pipeline optionality. Q3 looked weak, with ...

Signed, sealed and delivered, Metsera is finally Pfizer’s. Pfizer has completed its acquisition of the obesity biotech, capping a whirlwind two weeks in which rival pharma Novo Nordisk attempted to ...

Pfizer has won a $10 billion deal to acquire the fast-rising obesity drug developer Metsera, ending a fierce bidding war with Danish rival Novo Nordisk. Metsera accepted a sweetened offer from Pfizer ...

Pfizer has axed 11 programs including two pipeline assets from its $43 billion Seagen acquisition, work on a BioNTech-partnered mRNA vaccine and a midstage metabolic dysfunction-associated ...

President Donald Trump today, Sept. 30, announced TrumpRX, a new website for Americans to buy drugs, while he touted lower prices across Pfizer drugs, according to the Wall Street Journal. Trump ...

Proposed acquisition to add four highly differentiated clinical-stage incretin and amylin programs to Pfizer’s pipeline Transaction valued at $47.50 per Metsera share in cash upon closing, for an ...

Pfizer is one of the world's largest and oldest drug companies. Thanks to its Covid vaccine, shares rose dramatically during the pandemic. Now that the stock has sharply corrected, long-term investors ...

The advancement of Pfizer’s antibody-drug conjugate portfolio has not spared the former Seagen site—and those who helped develop the therapies—from layoffs. Pfizer is laying off 100 employees in ...

WASHINGTON — A former Pfizer scientist was subpoenaed Monday by House Republicans over allegations that senior executives at the pharma giant colluded to “deliberately slow down” clinical tests of its ...